版本:
中国

BRIEF-Amgen presents positive data at EHMTIC 2016, Erenumab reduces migraine

Sept 15 Amgen Inc :

* Amgen presents positive data at EHMTIC 2016 demonstrating erenumab significantly reduces monthly migraine days in patients with chronic migraine

* No adverse event was reported in greater than five percent of patients treated with Erenumab

* Amgen Inc says results from phase 3 studies investigating Erenumab in episodic migraine are expected later this year

* All groups showed numeric improvements in cumulative monthly headache hours

* Phase 2 results showing Erenumab demonstrated a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine

* Safety profile of Erenumab was similar to placebo across both treatment arms Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐